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CXCL12 expression is an adverse predictor
for disease recurrence in patients with
metastatic non-seminomatous testicular
germ cell tumors
Christian Daniel Fankhauser1*† , Lisa Roth1†, Nico Christian Grossmann1, Benedikt Kranzbühler1, Daniel Eberli1,
Tullio Sulser1, Holger Moch2, Peter-Karl Bode2, Joerg Beyer3 and Thomas Hermanns1
Abstract
Background: To validate the utility of the chemokine ligand 12 (CXCL12) as prognostic marker in patients with
localized and metastatic germ cell tumors (GCT).
Methods: CXCL12 expression was analyzed on a tissue microarray consisting of 750 tissue cores of different
histological tumor components, Germ cell neoplasia in situ (GCNIS) and adjacent normal tissue of 263 testicular
cancer patients using a semi-quantitative score. The association between CXCL12 expression and recurrence-free
survival (RFS) as well as overall survival (OS) was assessed using Kaplan-Meier curves with log-rank tests.
Results: CXCL12 expression was absent in all seminomas but was found in 52 of 99 (52.5%) non-seminomas.
Follow-up was available for 260 patients of which 36 (13.8%) recurred. In patients with stage 1 non-seminoma GCT,
CXCL12 expression was not associated with higher risk of disease recurrence (p = 0.270). In contrast, post
chemotherapy RFS of patients with metastatic non-seminoma and positive CXCL12 expression was significantly
shorter compared to CXCL12 negative patients (p = 0.003). OS differences were not statistically different between
patients with CXCL12 positive or negative tumors for either localized or metastatic disease.
Conclusions: CXCL12 is almost exclusively expressed in non-seminoma. Pure seminoma, GCNIS and adjacent
normal testicular tissue are CXCL12 negative. Our analysis suggests that patients with metastatic disease and a
CXCL12-positive non-seminoma are at higher risk for disease recurrence after first-line chemotherapy and might
thus be candidates for more intensive treatment and/or closer follow-up.
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Background
Testicular germ cell tumors (GCT) represent the most
common solid neoplasm of men in their third and fourth
decade [1]. Seventy percent of all patients are initially di-
agnosed with localized disease (i.e. stage I disease) [2]. If
the cancer is limited to the testicle, the therapy involves
surgical removal of the affected testicle, followed by a
strict surveillance program including regular blood tests,
x-rays and computerized tomography [3, 4]. Despite the
excellent prognosis of localized GCT, 15–30% of pa-
tients experience disease recurrence during surveillance
[5]. An option to reduce the risk of recurrence is the ad-
ministration of one cycle of adjuvant chemotherapy after
orchiectomy, which reduces the risk of disease recur-
rence substantially [6]. Attempts have been made to
stratify patients, who are at higher risk for disease recur-
rence based on different pathological characteristics (i.e.
the size of the tumor and rete testis infiltration or the
presence of lympho-vascular invasion and of embryonal
carcinoma) [6–10]. However, the discovery of new
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markers that more reliably predict the risk of recurrence
are of utmost importance.
Recently Gilbert et al. [11] were able to show that an
increased expression of the chemokine ligand 12
(CXCL12) in the primary tumor was associated with a
decreased relapse rate in patients with stage I non-semi-
noma. The authors concluded, that low CXCL12 expres-
sion might be a useful biomarker to identify patients
who are at lower risk of recurrence and thus good candi-
dates for active surveillance. However, those findings
were somewhat surprising since CXCL12 is known as
tumor promoting chemokine and high CXCL12 expres-
sion is actually associated with worse survival in most
cancers [12]. The aims of our study were to externally
validate the results of Gilbert et al. in patients with stage
I disease and to extend the analysis to patients with
metastatic GCT.
Methods
A consecutive series of patients with surgically resected
testicular GCT between 2000 and 2014 was evaluated.
Patients with bilateral testicular tumors, extra-gonadal
primary or missing follow-up data were excluded from
the analysis. Clinical characteristics (age, Body-Mass-
Index (BMI), histology of the primary tumor, staging
characteristics according to the tumor, nodes and metas-
tases system (TNM) of the American Joint Committee
on Cancer (AJCC) and to the International Germ Cell
Cancer Collaborative Group (IGCCCG) and blood-
based tumor markers (i.e. alpha-fetoprotein (AFP),
beta-human chorionic gonadotropin (b-hCG) and lac-
tate dehydrogenase (LDH)) as well as follow-up infor-
mation were extracted from the medical charts. The
study was approved by the local ethics committee
(KEK StV. 25–2008).
A tissue microarray (TMA) was constructed of forma-
lin-fixed, paraffin-embedded tumor tissue of all included
patients. If more than one tumor component was
present in one patient all different GCT components
were separately punched and included on the TMA. Tu-
mors were classified by an experienced uropathologist
(PKB) specialized in GCT pathology according to the
2016 WHO Classification [13]. Each tumor component
was represented by two 0.6 mm diameter cores. The
TMA was finally constructed with tissue cores of 263
GCT patients and included 99 Non-seminomas and 164
seminomas. The separately punched GCT components
included: 422 seminomas, 172 embryonal carcinomas, 65
yolk sac tumors, 29 teratomas, 7 choriocarcinomas and
9 germ cell neoplasia in situ (GCNIS). Additionally, adja-
cent normal testicular tissue of 40 GCT patients was
included.
Sections of 3 μm thickness of the TMA blocks were
mounted on glass slides (SuperFrost Plus; Menzel,
Braunschweig, Germany), deparaffinized, rehydrated and
stained with hematoxylin and eosin using standard
histological techniques. CXCL12 immunohistochemistry
was performed using the monoclonal CXCL12 antibody
(Antibody 79018, 1:100; R&D Systems Minneapolis MN,
USA). Peripheral neuronal tissue served as internal posi-
tive control for CXCL12 staining. The stained slides
were digitalized and evaluated using imaging software
(Spot browser, Alphelys, Plaisir, France). Two investiga-
tors (CDF, PKB) evaluated the CXCL12 staining of each
spot on the TMA. A patient’s tumor was classified as be-
ing positive if any of its components showed either mod-
erate or strong CXCL12 expression and negative if
CXCL12 expression was either absent or weak (Fig. 1).
Recurrence-free survival (RFS) and overall survival
(OS) were calculated from time of diagnosis to first re-
currence after initial management or death respectively.
RFS and OS of patients with CXCL12 positive and nega-
tive tumors were compared using Kaplan-Meier curves
and the log-rank test. Statistical analysis was performed
using IBM SPSS Statistics (Version 21.0, Armonk, New
York, USA: IBM Corp.). The results for continuous nor-
mally distributed variables are expressed as means ±
standard deviation (SD). Continuous non-normally dis-
tributed variables are presented as median and inter-
quartile ranges (IQR). The results for categorical
variables are presented as percentage. A p-value of <
0.05 was considered significant. All statistical tests were
two-sided.
Results
The mean age at diagnosis was 26 years and patients
were followed for a median of 64 months (Table 1). At
initial diagnosis 190 of 263 patients (72%), were classi-
fied as stage I, 4 patients (2%) as stage IS, 35 patients
(13%) as stage II and 34 patients (13%) as stage III. Of
132 patients with stage I seminoma, adjuvant chemo-
therapy with 1 cycle of carboplatin was administered to
70 patients (53%) and adjuvant radiotherapy to 6 pa-
tients (5%). Of 58 patients with stage I non-seminoma,
adjuvant chemotherapy with 1 cycle of bleomycin, etopo-
side and cisplatin (BEP) was administered to 13 patients
(22%). Of all 73 patients with metastases, 56 (76%) were
classified as good risk, 13 (18%) as intermediate risk and
4 (6%) as poor risk according to the IGCCCG classifica-
tion. All metastatic patients were treated with cisplatin
based chemotherapy, most commonly with BEP (83%).
Seven patients underwent retroperitoneal lymph node
dissection due to post-chemotherapy residual masses.
CXCL12 expression was negative in normal tissue,
GNCIS and seminoma tissue (Table 2). In patients with
non-seminoma, CXCL12 expression was found in 52 pa-
tients (52.5%). Non-seminoma patients with CXCL12 ex-
pression in their primary tumor had significantly higher
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pre-orchiectomy AFP values (118.7 μg/l vs. 5.3 μg/l, p <
0.001) and b-HCG values (152.0 U/l vs. 8.2 U/l, p <
0.001) compared to CXCL12 negative patients (Fig. 2).
In patients with localized non-seminoma, CXCL12 ex-
pression was not significantly associated with time to
disease recurrence (p = 0.27) or time to death (p = 0.17)
(Fig. 3). Also after controlling for adjuvant chemother-
apy, no significant association between CXCL12 expres-
sion and time to recurrence was observed (p = 0.4).
There was even a trend for a shorter time to recurrence
in patients with high CXCL12 expression.
In patients with metastatic non-seminoma CXCL12
expression was not associated with worse IGCCCG risk
groups (p = 0.66). In contrast, patients with metastatic
non-seminoma and higher CXCL12 expression showed a
significantly shorter time to disease recurrence (p =
0.03), whereas time to death was not significantly differ-
ent (p = 0.21) compared to CXCL12 negative patients.
Discussion
In this study CXCL12 expression was observed in a large
number of patients with non-seminoma but was absent
in normal tissue, GCNIS or seminoma. We were not
able to confirm the results by Gilbert and colleagues and
even found a trend for a higher risk of disease recur-
rence in patients with high CXCL12 expression. Simi-
larly to our results in stage I disease, CXCL12
expression was associated with a higher risk for disease
recurrence in patients with metastatic non-seminoma
after first line chemotherapy.
Table 1 Baselines characteristics
N = 263
Age (years) (±SD) 26.4 (8.9)
Seminoma 164 (62%)
Non-Seminoma or mixed GCT 99 (38%)
Clinical Stage (AJCC)
-Stadium I 190 (72%)
-Stadium IS 4 (2%)
-Stadium II 35 (13%)
-Stadium III 34 (13%)
IGCCCG risk groups
-Good risk 56 (21%)
-Intermediate risk 13 (5%)
-Poor risk 4 (2%)
AJCC American Joint Committee on Cancer, BMI Body-Mass-Index (kg/cm2),
IGCCCG International Germ Cell Cancer Collaborative Group, IQR Interquartile
Range, SD Standard deviation, TNM tumor, nodes and metastases system of
cancer staging
Fig. 1 Examples of absent (a), weak (b) moderate (c) and strong (d) CXCL12 in seminoma (a), embryonal carcinoma (b & d) and yolk sac (c)
tumor components
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The chemokine CXCL12 has important physiological
roles in embryonal development, vascular proliferation,
hematopoiesis, and inflammation by interaction with dif-
ferent receptors such as the CXC chemokine receptor 4
(CXCR4) [14–16]. CXCL12/CXCR4 interaction is also
known to be involved in tumor-promoting mechanisms
which result in increased proliferation, invasion, adhe-
sion, angiogenesis and decreased apoptosis [12]. High
CXCL12 expression is known to be associated with
worse survival in patients with different types of solid
cancers [12].
The role of CXCL12 in GCT is controversial. In con-
trast to most solid cancers Gilbert et al. found that
CXCL12 expression is a protective factor in patients
with stage 1 non-seminoma [12]. However, in our ana-
lysis we were not able to confirm these findings of
Gilbert and our analyses suggest that CXCL12 might
even be a risk factor and not a protective factor in stage
1 non-seminoma. Although both studies used the same
antibody, our TMA based approach might have missed
the heterogeneity of CXCL12 expression. As a conclu-
sion of those contradictory results we currently discour-
age clinicians to use CXCL12 for clinical decision
making until further studies clarify the role of CXCL12
in in stage 1 non-seminoma.
For metastatic GCTs, the IGCCCG classification is
currently recommended to counsel patients with meta-
static GCT regarding their risk of disease recurrence and
survival and to guide treatment for these patients [17].
This classification is based on the histological subtypes
(i.e. seminoma vs. non-seminoma), the location of the
primary tumor and of the metastases and the tumor
Table 2 CXL12 expression on single core level and patient level
Single Cores Semi-quantitative Score
negative weak moderate strong
Seminoma (n = 422) 421 (99.8%) 0 (0.0%) 0 (0.0%) 1 (0.2%)
Embryonal Carcinoma (n = 172) 123 (70.7%) 0 (0.0%) 8 (4.6%) 43 (24.7%)
Teratoma (n = 29) 19 (59.3%) 0 (0.0%) 2 (6.3%) 11 (34.4%)
Yolk sack Tumor (n = 65) 5 (7.6%) 1 (1.5%) 11 (16.7%) 49 (74.2%)
Chorion Carcinoma (n = 7) 0 (0.0%) 0 (0.0%) 1 (14.3%) 6 (85.7%)
Patient Level Dichotomized
Negative Positive
Non Seminoma or mixed GCT (n = 99) 47 (47.5%) 52 (52.5%)
Pure Seminoma (n = 164) 164 (100%) 0 (0.0%)
Normal tissue (n = 40) 40 (100%) 0 (0.0%)
GCNIS (n = 9) 9 (100%) 0 (0.0%)
Abbreviation: GCT germ cell tumor, GCNIS Germ cell neoplasia in situ
Fig. 2 Boxplots comparing AFP (a) and b-hCG (b) levels before orchiectomy between patients with negative and positive CXCL12 expression
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markers levels. Our results suggest that CXCL12 expres-
sion in the primary tumor may improve risk stratifica-
tion in patients with metastatic GCTs. Patients with
metastatic disease and CXCL12 positive primary tumors
may need more intense first-line chemotherapy and/or
at least a closer post-chemotherapy follow-up.
The present analysis is limited by its retrospective design,
single center approach and relatively small sample size. A
further limitation of our study is that we were not able to
perform a meaningful multivariate cox regression analysis
due to the limited number of events. Additionally, multiple
testing may lead to type I errors, which might overestimate
the described associations between CXCL12 expression
and oncologic outcomes. Thus, our analyses should rather
be considered exploratory. A larger dataset including lymph
vascular invasion status or IGCCCG classification is needed
to reliably assess a potential independent prognostic impact
of CXCL12 expression in localised and metastatic disease
respectively. Especially the planned IGCCCG update might
be an opportunity to elucidate whether CXCL12 would ul-
timately possess the potential to predict oncologic out-
comes besides the IGCCCG classification [18].
Conclusion
CXCL12 is exclusively expressed in non-seminoma
and absent in seminoma, normal tissue or GCNIS.
We were not able to show an association between
CXCL12 and lower recurrence rates in stage I non-
seminoma patients. However, positive CXCL12 ex-
pression was associated with shorter RFS after first-
line chemotherapy in patients with metastatic GCT
and thus might help to identify patients at a higher
risk for disease recurrence.
Fig. 3 Kaplan Meyer curves for recurrence free (top row) and overall survival (lower row) stratified by CXCL12 expression. In stage 1 non-
seminoma CXCL12 expression did neither predict recurrence free (top left corner) nor overall survival (lower right corner). In metastatic non-
seminoma CXCL12 expression predicted recurrence free (top right) but not overall survival (lower right)
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